User profiles for Juan Luis García-Rivero
Juan Luis Garcia RiveroNeumólogo, Hospital Universitario Marqués de Valdecilla, Santander Verified email at scsalud.es Cited by 1128 |
[HTML][HTML] Documento de consenso de asma grave en adultos. Actualización 2020
…, JL García-Rivero, A Padilla, L Pérez-de Llano… - Open Respiratory …, 2020 - Elsevier
El asma grave constituye un síndrome heterogéneo con múltiples variantes clínicas y
representa el último peldaño en la patología asmática en relación con su gravedad. La …
representa el último peldaño en la patología asmática en relación con su gravedad. La …
Documento de consenso sobre el diagnóstico y tratamiento de la infección bronquial crónica en la enfermedad pulmonar obstructiva crónica
…, MC Rubio, RC Moreno, JL García-Rivero… - Archivos de …, 2020 - Elsevier
A pesar de que es conocido que la presencia crónica de microorganismos en las vías
aéreas de pacientes con enfermedad pulmonar obstructiva crónica (EPOC) en fase de …
aéreas de pacientes con enfermedad pulmonar obstructiva crónica (EPOC) en fase de …
Sputum microbiome dynamics in chronic obstructive pulmonary disease patients during an exacerbation event and post-stabilization
JC López Caro, M Santibáñez, JL García Rivero… - Respiration, 2019 - karger.com
Background: Chronic obstructive pulmonary disease (COPD) affects up to 65 million people
worldwide, and COPD exacerbation causes tissue damage and subsequent loss of lung …
worldwide, and COPD exacerbation causes tissue damage and subsequent loss of lung …
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma …
…, A Mohan, A Burden, L McDermott… - The lancet respiratory …, 2021 - thelancet.com
Background ANDHI was done to assess the efficacy of benralizumab, including onset of effect
and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and …
and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and …
GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia
…, E Brague-Allegue, M Carrascosa, JL García-Rivero… - MedRxiv, 2020 - medrxiv.org
Background We aimed to determine whether a 6-day course of intravenous methylprednisolone
(MP) improves outcome in patients with SARS CoV-2 infection at risk of developing …
(MP) improves outcome in patients with SARS CoV-2 infection at risk of developing …
[HTML][HTML] Soporte telefónico al paciente con EPOC en tiempos de la COVID-19
JL Lopez-Campos, M Calle, BG Cosío… - Open Respiratory …, 2020 - Elsevier
La imposición del estado de alarma por el Gobierno Español como principal medida para
evitar el contagio ha supuesto un cambio en la aproximación clínica al paciente crónico. …
evitar el contagio ha supuesto un cambio en la aproximación clínica al paciente crónico. …
Asthma outcomes improve with continuous positive airway pressure for obstructive sleep apnea
…, FJ González‐Barcala, JL García‐Rivero… - Allergy, 2017 - Wiley Online Library
Background Continuous positive airway pressure ( CPAP ) in asthma patients with concomitant
obstructive sleep apnea syndrome ( OSAS ) seems to have a favorable impact on asthma…
obstructive sleep apnea syndrome ( OSAS ) seems to have a favorable impact on asthma…
Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease
…, MC Rubio, RC Moreno, JL García-Rivero… - Archivos de …, 2020 - Elsevier
Although the chronic presence of microorganisms in the airways of patients with stable
chronic obstructive pulmonary disease (COPD) confers a poor outcome, no recommendations …
chronic obstructive pulmonary disease (COPD) confers a poor outcome, no recommendations …
[HTML][HTML] Predictors of hospitalized exacerbations and mortality in chronic obstructive pulmonary disease
…, S Arenal, C Bonnardeux, C Leon, JL García-Rivero - PLoS …, 2016 - journals.plos.org
… García Rivero reports receiving consulting and/or speaking fees from Almirall, Boehringer-…
García Rivero, reports receiving consulting and/or speaking fees from Almirall, Boehringer …
García Rivero, reports receiving consulting and/or speaking fees from Almirall, Boehringer …
Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEV1, exacerbations, oral corticosteroids, symptoms …
…, C Colás, JL García-Rivero, L Carmona… - The Journal of Allergy …, 2021 - Elsevier
… JL García-Rivero received speaking or advisory fees, or economic aid, to attend
congresses, or participation in clinical studies on behalf of (alphabetical order): ALK, Astra-Zeneca, …
congresses, or participation in clinical studies on behalf of (alphabetical order): ALK, Astra-Zeneca, …